• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Beam Therapeutics Inc (NQ: BEAM )

    25.78 -1.15 (-4.27%)
    Streaming Delayed Price Updated: 2:24 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 879,170
    Open 26.84
    Bid (Size) 25.76 (3)
    Ask (Size) 25.80 (1)
    Prev. Close 26.93
    Today's Range 25.64 - 27.47
    52wk Range 16.95 - 49.50
    Shares Outstanding 79,199,501
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Beam Therapeutics Announces Transition of Chief Financial Officer
    From Beam Therapeutics
    Via GlobeNewswire
    The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
    Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge. 
    Via InvestorPlace

    Performance

    YTD
    -5.95%
    -5.95%
    1 Month
    +7.28%
    +7.28%
    3 Month
    +6.05%
    +6.05%
    6 Month
    +6.84%
    +6.84%
    1 Year
    -14.97%
    -14.97%

    More News

    Read More
    3 Stocks With the Potential to 10X Your Money
    Via InvestorPlace
    FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
    Via InvestorPlace
    Exposures Product Safety
    3 Stocks This Amazon-Backed AI Says Will Turn $1K into $1M by 2030
    Via InvestorPlace
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Expert Ratings For Beam Therapeutics
    Via Benzinga
    Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
    Via Benzinga
    Navigating 4 Analyst Ratings For Beam Therapeutics
    Via Benzinga
    You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
    Via InvestorPlace
    Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
    From Beam Therapeutics
    Via GlobeNewswire
    Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
    Via InvestorPlace
    Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference
    From Beam Therapeutics
    Via GlobeNewswire
    BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
    From Beam Therapeutics
    Via GlobeNewswire
    Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
    Via Benzinga
    Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
    Via Benzinga
    Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
    From Beam Therapeutics
    Via GlobeNewswire
    MarketBeat Week in Review – 3/4 – 3/8
    Via MarketBeat
    Topics Artificial Intelligence Economy
    Exposures Artificial Intelligence Interest Rates
    Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
    Via MarketBeat
    Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
    From Beam Therapeutics
    Via GlobeNewswire
    Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
    Via Investor's Business Daily
    Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.